Navigation Links
Thrombosis in Medical Technology

Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing

... today at the XXII International Society on thrombosis and Haemostasis Congress in Boston. Edoxaban is ... established by the International Society on thrombosis and Haemostasis(3), the most sensitive scale of ... products in non-surgical patients. Journal of thrombosis and Haemostasis 2005;3: 692-694. ...

ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402

... being developed for the prevention of deep vein thrombosis (DVT) following orthopaedic surgery. The decision ... the XXII Congress of the International Society on thrombosis and Haemostasis (ISTH) on July 15, 2009 in ... this product candidate." About Deep Vein thrombosis (DVT) DVT is caused when a blood clot ...

Isis and Collaborators Present New Research at the ATVB Annual Conference

... data were presented during the Arteriosclerosis, thrombosis and Vascular Biology's (ATVB) Annual Conference. ... drug candidate for development from our new thrombosis effort. It is another example of the power of ... Factor XI as the optimal target to inhibit thrombosis without causing bleeding. In addition to Factor ...

Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years

... for TAXUS, p-value=0.092)*. No stent thrombosis between two and three years with XIENCE V, and a low rate of stent thrombosis from zero to three years, per Academic Research ... (ARC) definition of definite/probable stent thrombosis (0.9 percent for XIENCE V and 2.8 percent for ...

March 2009 Mayo Clinic Health Letter Highlights Knee Repair Surgery, Anxiety Disorder and Preventing Blood Clots

... flights aren't the only risk factor for deep vein thrombosis (DVT), the medical term for blood clots in the ... For most healthy adults, deep vein thrombosis is extremely rare. Every year, about 350,000 ... are used to diagnose DVT. Treatment for deep vein thrombosis seeks to prevent the clot from becoming bigger ...

Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent

... p-value=0.07)*. -- Low rates of stent thrombosis (blood clotting within the treated area) per the ... (ARC) definition of definite/probable stent thrombosis (1.3 percent for XIENCE V vs. 1.7 percent for ... percent for TAXUS). The ARC definitions of stent thrombosis were developed to eliminate variability in the ...

Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention

... an important anti-platelet therapy in treating thrombosis patients in both the acute and chronic settings." ... receptor on platelets has been proven to prevent thrombosis and subsequent heart attacks. Portola believes ... ischemic events, and elective PCI. About thrombosis Thrombosis, or the development of harmful ...

Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer

... arterial thromboembolic events (i.e., deep-vein thrombosis of the lower and upper limbs, visceral and ... i n the Treat m ent of Deep-Venous thrombosis (EQUINOX Study): Safety, Efficacy, and ... patients with symptomatic and confirmed deep-vein thrombosis were randomized to receive weekly subcutaneous ...

Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders

... receptor on platelets has been proven to prevent thrombosis and subsequent heart attacks. Portola believes ... of Cardiovascular Research at the Center for thrombosis Research at Sinai Hospital, Baltimore, MD. ... achieved the predefined endpoint. Inhibition of thrombosis was highly significant in these non-responder ...

Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years

... TAXUS, p-value=0.03)*. -- Low rates of stent thrombosis between one and two years, defined as very late ... (ARC) definition of definite/probable stent thrombosis (0.5 percent for XIENCE V and 0.8 percent for TAXUS). The ARC definitions of stent thrombosis were developed to eliminate variability in the ...

Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent

... The adjusted rate of ARC definite/probable stent thrombosis at three years for the TAXUS Liberte Stent group ... adjusted rate of ARC definite/probable stent thrombosis for the direct stent group at 0.3 percent, as ... of 46 percent. ARC definite/probable total stent thrombosis at two years was 0.8 percent for the TAXUS ...

APTA Supports Surgeon General's 'Call to Action' to Prevent Deep Vein Thrombosis and Pulmonary Embolism

... MPH to reduce the number of cases of deep vein thrombosis and pulmonary embolism in the United States. ... Pulmonary Section, blood clots, called deep vein thrombosis (DVT), can occur after periods of being immobile, ... and prevention of symptomless deep-vein thrombosis in long-haul flights: a randomised trial. Lancet. ...

Surgeon General's 'Call to Action' to Prevent DVT/PE Praised by NATT as Turning Point

... -- The National Alliance for thrombosis and Thrombophilia (NATT) praised Acting ... to Action" (CTA) to prevent deep vein thrombosis (DVT) and pulmonary embolism (PE). RADM Galson ... NC In the past year, CDC has designated thrombosis as a priority, increasing surveillance of DVT/PE ...

TAXUS OLYMPIA Registry Shows Excellent Outcomes for High-Risk Patients Treated With Second-Generation TAXUS(R) Liberte(R) Stent

... re-intervention (TLR) (2.5%). The definite stent thrombosis rate was 0.8 percent after one year, which is ... stent-related composite cardiac events and stent thrombosis were 4.3 percent and 0.9 percent respectively. ... "The low occurrence of cardiac events and stent thrombosis is noteworthy, especially given the high degree ...

Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel

... reduced risk of heart attack and stent thrombosis compared with clopidogrel among ... was also a significantly lower rate of stent thrombosis among diabetes patients treated with prasugrel, ... in a 48 percent relative risk reduction in stent thrombosis compared with clopidogrel (3.6 percent vs. 2.0 ...

Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis

... peripheral conditions related to arterial thrombosis with a novel mechanism that may provide ... novel mechanism of action. About Thrombosis thrombosis is the formation of a clot, or thrombus, inside a ... and efficacy of APD791; the role of serotonin in thrombosis and in increasing cardiovascular risk; how ...

Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women

... the prevention and management of thrombosis in key patient populations and reinforce ... on the challenges in preventing and treating thrombosis in pregnant women and children, and on managing ... are used to prevent and treat thrombosis or blood clotting that arises in arteries, veins, ...

XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years

... Long-Term Clinical Outcomes, Lower Rates of Stent thrombosis than Patients Treated ... lower observed rates of late and very late stent thrombosis in XIENCE V-treated patients, especially in those ... for TAXUS, p-value=0.07)*. -- Low rates of stent thrombosis between one and two years, defined as very ...

TRITON-TIMI 38 Stent Analysis Favors Prasugrel

... since the stenting procedure, or the way stent thrombosis is defined. The results of the TRITON-TIMI 38 ... Overall, prasugrel reduced both early stent thrombosis -- within 30 days of stenting -- when compared ... hazard ratio 0.41, p<0.001) -- and late stent thrombosis -- more than 30 days after stenting (0.49 percent ...

Study Finds Repeated Episodes of Stent Thrombosis Common

... Treating stent thrombosis with another stent hikes the risk of repeat blood ... attack or even death. A single incident of stent thrombosis is bad enough, but a new study suggests that one ... total of 437 consecutive patients who had stent thrombosis confirmed by angiography between January 2004 and ...

Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel

... both BMS and DES at the time of enrollment. Stent thrombosis was a pre-defined secondary endpoint in the ... reduced the relative risk of coronary stent thrombosis (a new clot at the implanted stent site) over ... research consortium (ARC) definition of stent thrombosis was used - definite/confirmed stent thrombosis, ...

Long-Term Soliris(R) Therapy Improved or Stabilized Kidney Function in Patients With PNH

... Continued to Be Associated with Reductions in thrombosis and Improvements in Fatigue, Quality of Life, and ... was associated with sustained reduction in thrombosis and improvements in fatigue, overall quality of ... in Transfusion Requirements, Fatigue and thrombosis with Eculizumab Treatment in Paroxysmal Nocturnal ...

Addition of INTEGRILIN(R) (Eptifibatide) to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Coronary Stenting

... (NYSE: SGP ) and The Sinai Center for thrombosis Research at Sinai Hospital of Baltimore today ... Paul Gurbel, MD, Director of The Sinai Center for thrombosis Research, Sinai Hospital of Baltimore; ... Blood work was processed at The Sinai Center for thrombosis Research and the University of Oklahoma Health ...

Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial

... rates of death, myocardial infarction, and stent thrombosis across a broad cross section of patients and lesions and with no new cases of stent thrombosis between years four and five," said Gregg W. ... the TAXUS IV trial reported no cases of stent thrombosis between years four and five for the TAXUS Stent ...

Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial

... a difference in either acute (30 day) or late thrombosis rates between XIENCE V and TAXUS out to one year. ... a statistical difference between rates of stent thrombosis for XIENCE V or TAXUS out to one year in the SPIRIT III trial. Rates of late stent thrombosis at one year per protocol were 0.3 percent for ...

Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease

... analysis reported the overall incidence of stent thrombosis in the data set using the Academic Research ... and definite/probable/possible stent thrombosis rates for the CYPHER(R) Stent at three years were ... 5.3 percent and 6.4 percent, respectively. Stent thrombosis comparisons between the CYPHER(R) Stent and the ...

Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent

... the REALITY Trial investigators reported a stent thrombosis rate for the Taxus Stent that was significantly ... the difference between the protocol-defined stent thrombosis rate for each drug-eluting stent in the diabetic ... death, Q-wave myocardial infarction and stent thrombosis favoring the CYPHER(R) Stent were also seen in ...

Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent

... the bare-metal control experienced one stent thrombosis during this same period. This marks the third consecutive year of TAXUS II follow-up with no stent thrombosis seen in the TAXUS stent patient group. The ... data regarding late and very late stent thrombosis out to five years," said Prof. Sigmund ...

Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety

... difference between their rates of stent thrombosis (blood clots). "The five-year results of the ... a significant difference in the rates of stent thrombosis between the CYPHER(R) Stent and the bare metal ... were used, the rates of acute and subacute stent thrombosis were 0.0 percent for the bare metal stent and 1.1 ...

PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials

... that Soliris substantially reduced the risk of thrombosis in a diverse population of PNH ... the course of the disease.(3,4,5,6) An initial thrombosis increases the relative risk of death by five- to ... hemolysis in all treated patients and reduced thrombosis by 92 percent, with three events during Soliris ...

Value of Genetic Testing for Preventing Blood Clots Unproven, According to New AHRQ Study

... a history of blood clots helps to prevent a condition known as deep-vein thrombosis or to improve other clinical outcomes. The report, a summary of which ... As many as 600,000 Americans each year may have deep-vein thrombosis -- blood clots that form in the legs or pelvis. The condition occurs most ...

Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents

... Taxus(R) Liberte stent in high risk of restenosis patients. However, the thrombosis rate for Taxus treated patients increased from one to two years from 4.2% ... at 658 days in a patient who had previously presented with a subacute thrombosis and who was on dual antiplatelet therapy at the time of both thromboses. ...

Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine

... or its components, including death, repeat heart attack, stroke or stent thrombosis at one year. "The HORIZONS AMI trial provided outcomes data showing ... individual rates of death, repeat heart attack, stroke and stent thrombosis between the two groups through 12 months of follow-up, which persisted ...

New Study Suggests Rx Estrogen Delivery Through the Skin May Show Safety Benefits as Opposed to Oral Delivery

... blood. Platelets serve a central role in forming pathological arterial thrombosis that causes myocardial infarction and stroke. The study's authors further ... to identify postmenopausal women with an increased risk of arterial thrombosis or clotting before even starting estrogen therapy is an important goal to ...

Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial

... that the device was absorbed. In addition, there were no cases of thrombosis (blood clot formation) out to two years of follow-up, and no new major ... Key endpoints of the study include assessments of safety - MACE and stent thrombosis rates - at 30 days; six, nine, 12 and 18 months; and two years, with ...

The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent

... the following key results: A zero percent rate of stent thrombosis (blood clot formation) for all patients out to two years of follow up. ... Key endpoints of the study include assessments of safety - MACE and stent thrombosis rates - at 30 days, six, nine and 18 months, and one and two years, with ...

Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study

... option," said Richard Becker, MD, director of the Duke Cardiovascular thrombosis Center and lead author of the study. "TRA appears to work in a novel way ... which demonstrate the potential to address unmet medical needs. thrombosis may result in partial or complete blockage of arteries in the heart, brain ...

New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation

... evaluated using guidelines established by the International Society on thrombosis and Haemostasis(1), the most sensitive scale of those currently used in ... of antihemostatic medicinal products in non-surgical patients. Journal of thrombosis and Haemostasis 2005;3: 692-694. 2. Jorgensen, H.S., Nakayama, ...

Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM)

... were a target lesion revascularization (TLR) rate of 5%, a subacute thrombosis (SAT) rate of 0.4%, a late stent thrombosis (LST) rate of 0.3%, and a major adverse cardiac events (MACE) rate of ....

12-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions

... follow-up data from the ATLANTA Trial. The results include zero percent thrombosis in patients discontinuing dual anti-platelet therapy after only 30 days. ... FIM patient population, the results showed zero (0.0) percent stent thrombosis (Academic Research Consortium, or ARC-defined), death, myocardial ...
Other Contents
(Date:9/19/2014)... new study shows that legume plants regulate their ... molecules that are transmitted through the plant structure ... number of bacteria-holding nodules in the roots. This ... National Institute for Basic Biology, the Graduate University ... for Sustainable Resource Science in Japan. , ...
(Date:9/18/2014)... 18, 2014 New research into the Crimean-Congo hemorrhagic ... severe hemorrhagic disease in humans similar to that caused ... CCHFV infection. This discovery has the potential to lead ... , The research, reported in a paper ... and conducted by scientists at the Texas Biomedical Research ...
(Date:9/18/2014)... The fall foliage season that prompts millions of Americans to ... later and possibly last a little longer within a century, ... leaf peeping in some areas of the United States as ... report in the journal Global Ecology and Biogeography . ... that is the state tree of New Hampshire could ...
Breaking Biology News(10 mins):For legume plants, a new route from shoot to root 2Research milestone in CCHF virus could help identify new treatments 2Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4
(Date:9/20/2014)... TX (PRWEB) September 20, 2014 ... Forecast and Market Analysis to 2023?. The asthma ... decade, as it has become saturated with relatively ... inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists ... facing increasing generic competition. However, the launch of ...
(Date:9/20/2014)... September 20, 2014 Recently, Best ... site, has launched its new website. The new ... of popular hosting products for customers. Here, people ... make a purchasing decision. Also, it has recommended ... , One of the great web hosting ...
(Date:9/20/2014)... "As a nurse, patients always ask me how much ... Tamaqua, Pa. "The reason that they cannot tell is because ... My invention enables them to check oxygen levels on their ... it easier to monitor the contents of an oxygen tank. ... is low. It allows changeovers to be performed under optimal ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 Earlier this week, ... customers may have had their credit card information pilfered by ... spawning a slew of headline articles like this one ... the only eye opening numbers. , “Most people tend ... almost like it’s a way to score a game,” says ...
(Date:9/20/2014)... Final Cut Pro X Plugin developers ... Information theme for FCPX filmmakers. , “Fun, cool, and simple ... theme,” says Christina Austin, CEO of Pixel Film Studios. “It ... Information features easy to use controls that give the user ... the background color, color of each circle outline, the position ...
Breaking Medicine News(10 mins):Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 3Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 4Health News:Best Cheap Hosting USA Launches Its New Website And Recommends InMotion To Worldwide People 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 4Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 5Health News:Today Pixel Film Studios Announced the Release of the Information Theme for Final Cut Pro X 2
Other TagsOther Tags